MOD-GRF-1-29 (5MG)

Additional Info

Properties

• MOD-GRF-1-29 Chemical Formula: C152H252N44O42
• MOD-GRF-1-29 Molecular Weight: 3367.95 g/mol
• MOD-GRF-1-29 Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
• Total Amount of the Active Ingredient: 5mg (1 vial)
• Shelf Life: 36 months

Shipping

• USA
• Canada

Seizure Policy (International Orders)

If your shipment is seized, we offer a 50% discount on your next purchase. Please contact us for details.

Disclaimer

The information provided does not substitute medical advice, diagnosis, or treatment. For medical concerns, consult your physician or qualified healthcare provider promptly. Delaying medical advice based on information read or seen is not recommended. We hold no responsibility or liability for the use of our research compounds and products, which are intended strictly for research purposes. Personal use is strictly prohibited.

Additional Label & Product Information

Warnings:

• These chemicals are for research or laboratory use only. They are not approved by the FDA for human consumption.
• Avoid skin and eye contact. In case of contact, wash immediately with plenty of water.
• Seek medical advice if feeling unwell or in case of accidental ingestion.
• Store the lyophilised (freeze-dried) peptide at room temperature upon receipt to maintain stability. Avoid frequent freeze-thaw cycles.

Product Disclaimer:

This product is not intended to diagnose, treat, cure, or prevent any disease. Use only as specified by your research or laboratory protocol.

Resources

1. Wehrenberg WB, Ling N. Evaluation of the biological effectiveness of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor in vivo. Biochem Biophys Res Commun. 1983 Sep 15;115(2):525-30. doi: 10.1016/s0006-291x(83)80176-4. PMID: 6414471.
2. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and potential therapeutic applications of growth hormone-releasing hormone agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. doi: 10.1210/en.2019-00111. PMID: 31070727.
3. Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. Gastrointestinal side effects of a potential therapeutic growth hormone-releasing factor analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. doi: 10.1016/s0196-9781(01)00436-3. PMID: 11445245.
4. Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogues with vasoactive intestinal peptide (VIP) receptors of the rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology. 1985 Jun;116(6):2643-9. doi: 10.1210/endo-116-6-2643. PMID: 2859987.
5. Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. doi: 10.1111/j.1365-2265.1986.tb01666.x. PMID: 3098458.